REMission INDuction in very early Rheumatoid Arthritis - REMINDRA

niversity Medical Center Utrecht (UMCU)0 sites267 target enrollmentSeptember 28, 2016

Overview

No summary available.

Registry

who.int

Start Date

September 28, 2016

End Date

TBD

Last Updated

6 years ago

Study Type

Interventional clinical trial of medicinal product

Sponsor

niversity Medical Center Utrecht (UMCU)

•To be eligible to participate in this study, a subject must meet all of the following criteria:
•\-Able and willing to give written informed consent
•\-At least 18 years of age
•\-Fulfilling 2010 ACR/EULAR criteria for RA (Appendix A.)
•\-Patient reported symptom duration (joint stiffness, tenderness, pain, and/or swelling) \< 12 months
•\-Naïve for DMARD and biological treatment
•\-Naïve for previous use of glucocorticoids for RA
•\-DAS28 \=\>3\.2
•\-Have sufficient knowledge of the Dutch language to be able to comply with the requirements of the study protocol
•Are the trial subjects under 18? no

•A potential subject who meets any of the following criteria will be excluded from participation in this study:
•\-Being pregnant or a nursing women or a women of child bearing potential without (adequate) use of contraception
•\-Having any other inflammatory rheumatic disease than RA, except for secondary Sjögren’s syndrome
•\-Having contraindications for the use of MTX/HCQ/methylprednisolone/GOL.